Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2014 - 2024)
Palvella Therapeutics (PVLA) reported Depreciation & Amortization (CF) of -$30000.0 for Q1 2024, down 104.96% year-over-year from $605000.0 in Q2 2023, and up 84.85% quarter-over-quarter from -$198000.0 in Q4 2023.
Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of Depreciation & Amortization (CF) data on file, last reported at -$30000.0 in Q1 2024.
- Depreciation & Amortization (CF) for Q1 2024 came in at -$30000.0, down 104.96% year-over-year; the trailing twelve-month figure through Dec 2024 was -$30000.0 (down 101.58% YoY), and the FY2023 annual result was $1.9 million, down 31.26% from the prior year.
- Depreciation & Amortization (CF) improved to -$30000.0 in Q1 2024 per PVLA's latest filing, from -$198000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $845000.0 in Q1 2022 and troughed at -$198000.0 in Q4 2023.
- A 5-year average of $553764.7 and a median of $609000.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2020 and 2023: Depreciation & Amortization (CF) soared 1161.9% in 2020, then slumped 134.43% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $688000.0 in 2020, then retreated by 11.48% to $609000.0 in 2021, then declined by 5.58% to $575000.0 in 2022, then tumbled by 134.43% to -$198000.0 in 2023, then soared by 84.85% to -$30000.0 in 2024.
- Business Quant data shows PVLA's Depreciation & Amortization (CF) at -$30000.0 in Q1 2024, -$198000.0 in Q4 2023, and $739000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -30,000.00 |
| Mar 31, 2024 | -30,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Dec 31, 2021 | 609,000.00 |
| Dec 31, 2021 | 609,000.00 |